These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31077596)

  • 1. Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
    Rudulier CD; Tonti E; James E; Kwok WW; Larché M
    Allergy; 2019 Nov; 74(11):2157-2166. PubMed ID: 31077596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects.
    Couroux P; Patel D; Armstrong K; Larché M; Hafner RP
    Clin Exp Allergy; 2015 May; 45(5):974-981. PubMed ID: 25600085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy.
    Moldaver DM; Bharhani MS; Rudulier CD; Wattie J; Inman MD; Larché M
    J Allergy Clin Immunol; 2019 Mar; 143(3):1087-1099.e4. PubMed ID: 29906527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study.
    Smith TR; Alexander C; Kay AB; Larché M; Robinson DS
    Allergy; 2004 Oct; 59(10):1097-101. PubMed ID: 15355469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract.
    Ewbank PA; Murray J; Sanders K; Curran-Everett D; Dreskin S; Nelson HS
    J Allergy Clin Immunol; 2003 Jan; 111(1):155-61. PubMed ID: 12532112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization.
    Renand A; Archila LD; McGinty J; Wambre E; Robinson D; Hales BJ; Thomas WR; Kwok WW
    J Allergy Clin Immunol; 2015 Dec; 136(6):1627-1635.e13. PubMed ID: 26371841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects.
    Alexander C; Ying S; B Kay A; Larché M
    Clin Exp Allergy; 2005 Jan; 35(1):52-8. PubMed ID: 15649266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.
    Curin M; Weber M; Thalhamer T; Swoboda I; Focke-Tejkl M; Blatt K; Valent P; Marth K; Garmatiuk T; Grönlund H; Thalhamer J; Spitzauer S; Valenta R
    Clin Exp Allergy; 2014 Jun; 44(6):882-94. PubMed ID: 24552249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.
    Worm M; Lee HH; Kleine-Tebbe J; Hafner RP; Laidler P; Healey D; Buhot C; Verhoef A; Maillère B; Kay AB; Larché M
    J Allergy Clin Immunol; 2011 Jan; 127(1):89-97, 97.e1-14. PubMed ID: 21211644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major cat allergen, Fel d 1, in diagnosis and therapy.
    Grönlund H; Saarne T; Gafvelin G; van Hage M
    Int Arch Allergy Immunol; 2010; 151(4):265-74. PubMed ID: 19844127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen.
    Reefer AJ; Carneiro RM; Custis NJ; Platts-Mills TA; Sung SS; Hammer J; Woodfolk JA
    J Immunol; 2004 Mar; 172(5):2763-72. PubMed ID: 14978075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats.
    Pène J; Desroches A; Paradis L; Lebel B; Farce M; Nicodemus CF; Yssel H; Bousquet J
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):571-8. PubMed ID: 9802364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic analysis of perennial airborne allergen-specific CD4+ T cells in atopic and non-atopic individuals.
    Crack LR; Chan HW; McPherson T; Ogg GS
    Clin Exp Allergy; 2011 Nov; 41(11):1555-67. PubMed ID: 21729183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of peptide therapy on ex vivo T-cell responses.
    Marcotte GV; Braun CM; Norman PS; Nicodemus CF; Kagey-Sobotka A; Lichtenstein LM; Essayan DM
    J Allergy Clin Immunol; 1998 Apr; 101(4 Pt 1):506-13. PubMed ID: 9564804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine.
    Zaleska A; Eiwegger T; Soyer O; van de Veen W; Rhyner C; Soyka MB; Bekpen C; Demiröz D; Treis A; Söllner S; Palomares O; Kwok WW; Rose H; Senti G; Kündig TM; Ozoren N; Jutel M; Akdis CA; Crameri R; Akdis M
    Allergy; 2014 Sep; 69(9):1162-70. PubMed ID: 24934402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
    Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
    [No Abstract]   [Full Text] [Related]  

  • 18. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.
    Patel D; Couroux P; Hickey P; Salapatek AM; Laidler P; Larché M; Hafner RP
    J Allergy Clin Immunol; 2013 Jan; 131(1):103-9.e1-7. PubMed ID: 22981787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis.
    Worm M; Patel D; Creticos PS
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1347-57. PubMed ID: 23964728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-T-cell strategies in the treatment of allergic disease.
    Larché M
    Allergy; 2002; 57 Suppl 72():20-3. PubMed ID: 12144549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.